Literature DB >> 17485697

HER2 testing: the patent "genee" is out of the bottle.

Brian Goldman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17485697      PMCID： PMC1863548          DOI： 10.1503/cmaj.070423

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Diagnostic testing fails the test.

Authors:  Jon F Merz; Antigone G Kriss; Debra G B Leonard; Mildred K Cho
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

2.  Intellectual property. Enhanced: intellectual property landscape of the human genome.

Authors:  Kyle Jensen; Fiona Murray
Journal:  Science       Date:  2005-10-14       Impact factor: 47.728

3.  A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

Authors:  J Norum; T Risberg; J A Olsen
Journal:  Ann Oncol       Date:  2005-04-22       Impact factor: 32.976

4.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

Review 5.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.

Authors:  Nandini Dendukuri; Karim Khetani; Michelle McIsaac; James Brophy
Journal:  CMAJ       Date:  2007-05-08       Impact factor: 8.262
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.